Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press17110.17650/1726-9776-2013-9-1-34-42DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряPROGNOSTIC FACTORS OF SURVIVAL IN NON-MUSCLE-INVASIVE BLADDER CANCERФАКТОРЫ ПРОГНОЗА ВЫЖИВАЕМОСТИ У БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯAlekseevB. Ya.АлексеевБ. Я.
Russian Federation

Department of Oncourology

Отделение онкоурологии

inna.novikova.md@gmail.comAndreevaYu YuАндрееваЮ. Ю.
Russian Federation

Department of Human Pathology

Отделение патологической анатомии

inna.novikova.md@gmail.comNovikovaI. V.НовиковаИ. В.
Russian Federation

Department of Oncourology

Отделение онкоурологии

inna.novikova.md@gmail.comRussian Agency for Medical Technologies P.A. Herzen Moscow Research Oncological InstituteФГУ МНИОИ им. П.А. ГерценаMoscow City Clinical Hospital Fifty SevenГБУЗ ГКБ № 57, Москва300320139134423007201430072014https://oncourology.abvpress.ru/oncur/article/view/171

Most cases of new-onset non-muscle-invasive bladder cancer (NMIBC) show a propensity for frequent relapses, commonly progression to invasive cancer, and a significant difference in the long-term results of treatment in patients from one classification subgroup. The role of multiple prognostic clinical, histological, and biological factors is being widely discussed in the literature; however, the results of investigations in this area are contradictory and irreproducible. The problems in the prediction of the course of NMIBC remain to be solved.

Для большинства случаев впервые выявляемого немышечно-инвазивного рака мочевого пузыря (НМИ РМП) характерны склонность к частому рецидивированию, нередко прогрессия к инвазивному раку, а также существенное различие отдаленных результатов лечения пациентов из одной классификационной подгруппы. В литературе широко обсуждается роль многочисленных клинических, гистологических и биологических факторов прогноза, однако результаты исследований в данной области противоречивы или невоспроизводимы. Проблемы прогнозирования течения НМИ РМП остаются неразрешенными.

bladder cancerprognostic factorssurvival, recurrencetumor progressionрак мочевого пузыряфакторы прогнозавыживаемостьрецидивированиеопухолевая прогрессия1. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012.Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2012.2. Kirkali Z., ChanT., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(l6A):4 –34.Kirkali Z., ChanT., Manoharan M. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66(l6A):4 –34.3. European Association of Urology, Guidelines 2010.European Association of Urology, Guidelines 2010.4. Heney N.M., Ahmed F., Flanagan M.J. et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083 –1086.Heney N.M., Ahmed F., Flanagan M.J. et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083 –1086.5. Babjuk M., Oosterlinck W., Sylvester R. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladdeк,the 2011 Update. Eur Urol 2011; 59:997–1008.Babjuk M., Oosterlinck W., Sylvester R. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladdeк,the 2011 Update. Eur Urol 2011; 59:997–1008.6. Soloway M.S. It is time to abandon the ‘‘superficial’’ in bladder cancer. Eur Urol 2007;52:1564–5.Soloway M.S. It is time to abandon the ‘‘superficial’’ in bladder cancer. Eur Urol 2007;52:1564–5.7. Van Rhijn B.W., Burger M., Lotan Y. et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56(3):430–42.Van Rhijn B.W., Burger M., Lotan Y. et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56(3):430–42.8. Sylvestr R.J., van der Meijden A., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3): 466–77.Sylvestr R.J., van der Meijden A., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta-T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3): 466–77.9. Sanyal S., de Verdier P.J., Steineck G. еt al. Polimorphisms in XPD, XPS and the risk of death in patients with urinary bladder neoplasms. Acta Oncol 2007;46:31–41.Sanyal S., de Verdier P.J., Steineck G. еt al. Polimorphisms in XPD, XPS and the risk of death in patients with urinary bladder neoplasms. Acta Oncol 2007;46:31–41.10. Van den Bosch S., Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60(3):493–500.Van den Bosch S., Alfred Witjes J. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol 2011;60(3):493–500.11. Матвеев Б.П., Матвеев В.Б., Давыдов М.И. и др. Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: АБВ-пресс, 2011; с. 309–314.Матвеев Б.П., Матвеев В.Б., Давыдов М.И. и др. Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: АБВ-пресс, 2011; с. 309–314.12. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J. et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004;122(3):444–52.Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J. et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 2004;122(3):444–52.13. Mori Y., Arima M., Sbimada K. et al. Treatment of 300 patients with bladder сancer. Hinyokika Kiyo 1991;37(10):1235–41.Mori Y., Arima M., Sbimada K. et al. Treatment of 300 patients with bladder сancer. Hinyokika Kiyo 1991;37(10):1235–41.14. Jancke G., Rosell J., Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand J Urol Nephrol 2011;45(6):388–92.Jancke G., Rosell J., Jahnson S. Impact of tumour size on recurrence and progression in Ta/T1 carcinoma of the urinary bladder. Scand J Urol Nephrol 2011;45(6):388–92.15. Jimenez Cruz J.F., Llopis Mingues B., Vera-Donoso C. Primary superficial bladder cancer. Prognostic factors for reccurence. Arh Esp Urology 1990;43(2):139-47.Jimenez Cruz J.F., Llopis Mingues B., Vera-Donoso C. Primary superficial bladder cancer. Prognostic factors for reccurence. Arh Esp Urology 1990;43(2):139-47.16. Vukomanovic I., Colovic V., Soldatovic I., Hadzi-Djokic J. Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer. Med Oncol 2011;29(3):1916–20.Vukomanovic I., Colovic V., Soldatovic I., Hadzi-Djokic J. Prognostic significance of tumor location in high-grade non-muscle-invasive bladder cancer. Med Oncol 2011;29(3):1916–20.17. Divrik R.T., Sahin A., Altok M. et al. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J Urol 2007;178(3 Pt 1):802–6.Divrik R.T., Sahin A., Altok M. et al. The frequency of hydronephrosis at initial diagnosis and its effect on recurrence and progression in patients with superficial bladder cancer. J Urol 2007;178(3 Pt 1):802–6.18. Stimson C.J., Cookson M.S., Barocas D.A. et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 2010;183(5):1732–7.Stimson C.J., Cookson M.S., Barocas D.A. et al. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. J Urol 2010;183(5):1732–7.19. Palou J., Sylvester R.J., Rodriguez Faba O. et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118–25.Palou J., Sylvester R.J., Rodriguez Faba O. et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118–25.20. Touloupidis S., Fatles G., Kalaitzis C. et al. The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 2006;38(2):231–6.Touloupidis S., Fatles G., Kalaitzis C. et al. The significance of p53 and bcl-2 overexpression and other prognostic factors in transitional cell carcinoma of the bladder. Int Urol Nephrol 2006;38(2):231–6.21. Fajkovic H., Halpern J.A., Cha E.K. et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29(4):457–63.Fajkovic H., Halpern J.A., Cha E.K. et al. Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29(4):457–63.22. Mallin K., David K.A., Carroll P.R. et al. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol 2011;185(5):1631–6.Mallin K., David K.A., Carroll P.R. et al. Transitional cell carcinoma of the bladder: racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol 2011;185(5):1631–6.23. Griebling T.L. Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer. J Urol 2011;185(2):466–7.Griebling T.L. Impact of patient age on outcome following bladder-preserving treatment for non-muscle-invasive bladder cancer. J Urol 2011;185(2):466–7.24. Ha M.S., Chang I.H. Significance of age and comorbidity as prognostic indicators for patients with bladder cancer. Asian J Androl 2010;12(5):766–74.Ha M.S., Chang I.H. Significance of age and comorbidity as prognostic indicators for patients with bladder cancer. Asian J Androl 2010;12(5):766–74.25. Megwalu I.I., Vlahiotis A., Radwan M. et al. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol 2008;53(3):581–9.Megwalu I.I., Vlahiotis A., Radwan M. et al. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol 2008;53(3):581–9.26. Leliveld A.M., Bastiaannet E., Doornweerd B.H. et al. High risk bladder cancer: current management and survival. Int Braz J Urol 2011;37(2):203–10.Leliveld A.M., Bastiaannet E., Doornweerd B.H. et al. High risk bladder cancer: current management and survival. Int Braz J Urol 2011;37(2):203–10.27. Hwang E.C., Kim Y.J., Hwang I.S. et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 2011;18(11):769–76.Hwang E.C., Kim Y.J., Hwang I.S. et al. Impact of diabetes mellitus on recurrence and progression in patients with non-muscle invasive bladder carcinoma: a retrospective cohort study. Int J Urol 2011;18(11):769–76.28. Lammers R.J., Witjes W.P., Hendricksen K. et al. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol 2011;60(4):713–20.Lammers R.J., Witjes W.P., Hendricksen K. et al. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol 2011;60(4):713–20.29. Завалишина Л.Э., Андреева Ю.Ю., Маныкин А.А., Франк Г.А. Выявление вируса папилломы человека при опухолях эпителиальной природы. Пособие для врачей. М.: МНИОИ им. П.А. Герцена, 2004.Завалишина Л.Э., Андреева Ю.Ю., Маныкин А.А., Франк Г.А. Выявление вируса папилломы человека при опухолях эпителиальной природы. Пособие для врачей. М.: МНИОИ им. П.А. Герцена, 2004.30. Андреева Ю.Ю., Завалишина Л.Э., Морозов А.А. и др. Выявление ДНК вируса папилломы человека в поверхостной уротелиальной карциноме мочевого пузыря. Онкоурология 2008;(1):34-5.Андреева Ю.Ю., Завалишина Л.Э., Морозов А.А. и др. Выявление ДНК вируса папилломы человека в поверхостной уротелиальной карциноме мочевого пузыря. Онкоурология 2008;(1):34-5.31. Lopes-Beltran A., Escudero A.L., Vicioso L. et al. Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br J Cancer 1996;73:124–7.Lopes-Beltran A., Escudero A.L., Vicioso L. et al. Human papillomavirus DNA as a factor determining the survival of bladder cancer patients. Br J Cancer 1996;73:124–7.32. De Gaetani C., Ferrari G., Righi E. et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridization. J Clin Pathol 1999;52:103–6.De Gaetani C., Ferrari G., Righi E. et al. Detection of human papillomavirus DNA in urinary bladder carcinoma by in situ hybridization. J Clin Pathol 1999;52:103–6.33. Bassi P., Ferrante G.D., Piazza N. et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of homogeneous patient cohort. J Urol 1999;161(5):1494–7.Bassi P., Ferrante G.D., Piazza N. et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of homogeneous patient cohort. J Urol 1999;161(5):1494–7.34. Van Rhijn B.W., van der Kwast T.H., Alkhateeb S.S. et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61(2): 378–84.Van Rhijn B.W., van der Kwast T.H., Alkhateeb S.S. et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61(2): 378–84.35. Kruger S., Mahnken A., Kausch I. et al. (2005) P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 47(4):463 –7.Kruger S., Mahnken A., Kausch I. et al. (2005) P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 47(4):463 –7.36. Андреева Ю.Ю. Морфологические и молекулярно-биологические факторы прогноза рака мочевого пузыря. Дис. … докт. мед. наук. М., 2009.Андреева Ю.Ю. Морфологические и молекулярно-биологические факторы прогноза рака мочевого пузыря. Дис. … докт. мед. наук. М., 2009.37. Kurt K. et al. The natural history and the prognosis of tread superficial bladder cancer. EORTS GU Group// Prog Clin Biol Res 1992;378:1.Kurt K. et al. The natural history and the prognosis of tread superficial bladder cancer. EORTS GU Group// Prog Clin Biol Res 1992;378:1.38. Segal R., Yafi F.A., Brimo F. et al. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012;109(7):1026–30.Segal R., Yafi F.A., Brimo F. et al. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012;109(7):1026–30.39. Аничков Я.М., Толыбеков А.С. Уротелий: норма, воспаление, опухоль. Алма-Ата, 1987; с. 5090.Аничков Я.М., Толыбеков А.С. Уротелий: норма, воспаление, опухоль. Алма-Ата, 1987; с. 5090.40. Lipponen P.K., Eskelinen M.J., Jauhianinen K. et al. Clinical prognostic factors in transitional cell cancer of the bladder. Urol Int 1993;50(4):192–7.Lipponen P.K., Eskelinen M.J., Jauhianinen K. et al. Clinical prognostic factors in transitional cell cancer of the bladder. Urol Int 1993;50(4):192–7.41. Bertz S., Otto W., Denzinger S. et al. Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer. Eur Urol 2012 May.Bertz S., Otto W., Denzinger S. et al. Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer. Eur Urol 2012 May.42. Korneyev I.A. Prognostic factors in urinary bladder cancer patients // Eur Urol Today 1997;7(2):13.Korneyev I.A. Prognostic factors in urinary bladder cancer patients // Eur Urol Today 1997;7(2):13.43. Van der Poel Н.G., van Caubergh R.D., Boon M.E. et al. Kariometry in recurrent superficial transitorial cell tumors of the bladder. Urol Res 1992;20(5):375–81.Van der Poel Н.G., van Caubergh R.D., Boon M.E. et al. Kariometry in recurrent superficial transitorial cell tumors of the bladder. Urol Res 1992;20(5):375–81.44. Toyota K., Nagamori S., Kashiwagi A. et al. Flow cytometric analysis of the DNA content in the urinary bladder cancers treated by radical cystectomy and pre_operative irradiation. Nippon Hiyokika Gakkai Zasshi 1992;83(12):2050–7.Toyota K., Nagamori S., Kashiwagi A. et al. Flow cytometric analysis of the DNA content in the urinary bladder cancers treated by radical cystectomy and pre_operative irradiation. Nippon Hiyokika Gakkai Zasshi 1992;83(12):2050–7.45. Wang X.Z., Ma Y.J., Zheng J.F., Qin H.Y. DNA malignancy grading of bladdertumor and its clinical significance. Chin Med J Engl 1992;105 (10):856–9.Wang X.Z., Ma Y.J., Zheng J.F., Qin H.Y. DNA malignancy grading of bladdertumor and its clinical significance. Chin Med J Engl 1992;105 (10):856–9.46. Mhawech-Fauceglia P., Cheney R.T., Fischer G. et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32(2):231–7.Mhawech-Fauceglia P., Cheney R.T., Fischer G. et al. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol 2006;32(2):231–7.47. Karamitopoulou E., Rentsch C.A., Markwalder R. et al. Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens. Pathology 2010;42(1):37–42.Karamitopoulou E., Rentsch C.A., Markwalder R. et al. Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens. Pathology 2010;42(1):37–42.48. Wolf H.K., Stöber C., Hohenfellner R., Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol 2001;22(5):328–36.Wolf H.K., Stöber C., Hohenfellner R., Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1 G3 urothelial bladder carcinomas. Tumour Biol 2001;22(5):328–36.49. Erill N., Colomer A., Verdú M., Román R. et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol 2004;13(4):217–23.Erill N., Colomer A., Verdú M., Román R. et al. Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression. Diagn Mol Pathol 2004;13(4):217–23.50. Rammeh-Rommani S., Zermani R., Sfaxi M. et al. Prognostic value of the immunohistochemical expression of: Ki-67, p53, PCNA and Bc-l2 in the superficial tumors of the bladder. Tunis Med 2007;85(6):509–12.Rammeh-Rommani S., Zermani R., Sfaxi M. et al. Prognostic value of the immunohistochemical expression of: Ki-67, p53, PCNA and Bc-l2 in the superficial tumors of the bladder. Tunis Med 2007;85(6):509–12.51. Ong F., Moonen L.M., Gallee M.P. et al. Prognostic factor in transitional cell cancer of the bladder: an emerging role for bcl-2 and p53. Radioter Oncol 2001;61:169–75.Ong F., Moonen L.M., Gallee M.P. et al. Prognostic factor in transitional cell cancer of the bladder: an emerging role for bcl-2 and p53. Radioter Oncol 2001;61:169–75.52. Bustos A., Nascimento C.M., Fernandez F. et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6(9):678–86.Bustos A., Nascimento C.M., Fernandez F. et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005;6(9):678–86.53. Goebell P.J., Groshen S.G., Schmitz-Dräger B.J. International Study-Initiative on Bladder Cancer (ISBC). p53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol 2010;28(4):377–88.Goebell P.J., Groshen S.G., Schmitz-Dräger B.J. International Study-Initiative on Bladder Cancer (ISBC). p53 immunohistochemistry in bladder cancer-a new approach to an old question. Urol Oncol 2010;28(4):377–88.54. Cai T., Piazzini M., Nesi G. et al. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study. Oncol Rep 2007;17(4):925–30.Cai T., Piazzini M., Nesi G. et al. E-cadherin mRNA expression analysis in evaluating the natural history of urothelial bladder cell carcinoma: results from a long-term follow-up study. Oncol Rep 2007;17(4):925–30.55. Muramaki M., Miyake H., Terakawa T. et al. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 2010;5.Muramaki M., Miyake H., Terakawa T. et al. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol 2010;5.56. Baumgart E., Cohen M.S., Silva Neto B. et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007;13(6):1685–94.Baumgart E., Cohen M.S., Silva Neto B. et al. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 2007;13(6):1685–94.57. Szarvas T., Hoffmann F., Becker M. et al. Plasma E-cadherin levels in urinary bladdercancer: does it improve risk stratification? Urologe A 2011;50(1):64–70.Szarvas T., Hoffmann F., Becker M. et al. Plasma E-cadherin levels in urinary bladdercancer: does it improve risk stratification? Urologe A 2011;50(1):64–70.58. Levine A.I., Schmidek H.H. Molecular genetics of nervous system tumors. New-York, Wiley-Liss., 1993.Levine A.I., Schmidek H.H. Molecular genetics of nervous system tumors. New-York, Wiley-Liss., 1993.59. Brunner A., Mayerl C., Tzankov A. et al. Prognostic significance of tenascin C expression in superficial and invasive bladder cancer. J Clin Pathol 2004;57(9):927–31.Brunner A., Mayerl C., Tzankov A. et al. Prognostic significance of tenascin C expression in superficial and invasive bladder cancer. J Clin Pathol 2004;57(9):927–31.60. Richter P., Tost M., Franz M. et al. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 2009;135(10):1351–8.Richter P., Tost M., Franz M. et al. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? J Cancer Res Clin Oncol 2009;135(10):1351–8.